Abstract
Background Chronic Obstructive Pulmonary Disease (COPD) is a prevalent respiratory condition associated with systemic inflammation and various comorbidities, significantly impacting patients’ health outcomes. This study investigates the relationships between inflammatory biomarkers in COPD and their associations with comorbidities. By focusing on specific biomarkers such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-ALFA), and fibrinogen, we seek to find the complex interplay between systemic inflammation, COPD severity, and the prevalence of comorbidities. This research is critical for advancing our understanding of the systemic manifestations of COPD and informing targeted interventions for improved patient management. Methods This cross-sectional observational study will be conducted at AVBRH, a tertiary care hospital in central India, over two years (August 2022 to August 2024). A sample size of 90 COPD patients will be randomly selected based on inclusion and exclusion criteria. Diagnostic tests will be performed, including pulmonary function tests, chest X-rays, and biomarker assessments. Statistical analyses, encompassing chi-square tests, Pearson’s correlation coefficient, and logistic regression, will explore associations between inflammatory biomarkers, COPD severity, and comorbidities. The study design ensures rigorous data collection and adherence to ethical standards, with SPSS 27.0 utilized for statistical analyses. Expected Outcome Anticipated outcomes include a comprehensive understanding of how inflammatory biomarkers correlate with the severity of COPD and their associations with comorbidities. We expect to identify specific biomarkers that may serve as indicators of increased risk for certain comorbid conditions. The findings will contribute valuable insights into the systemic nature of COPD and inform healthcare strategies tailored to mitigate comorbidity-related risks in COPD patients. This research has the potential to enhance clinical decision-making, guide personalized treatment plans, and ultimately improve the overall management of individuals living with COPD.